Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Hematopoietic Stem Cell Transplantation | 74 | 2023 | 6550 | 3.800 |
Why?
|
Bone Marrow Transplantation | 62 | 2014 | 1581 | 2.860 |
Why?
|
Transplantation Conditioning | 31 | 2022 | 2238 | 2.120 |
Why?
|
Graft vs Host Disease | 44 | 2023 | 2638 | 1.490 |
Why?
|
Transplantation, Homologous | 38 | 2022 | 2843 | 1.260 |
Why?
|
Peripheral Blood Stem Cell Transplantation | 4 | 2020 | 216 | 1.100 |
Why?
|
Precursor Cell Lymphoblastic Leukemia-Lymphoma | 26 | 2023 | 2796 | 0.990 |
Why?
|
Child, Preschool | 95 | 2023 | 16273 | 0.970 |
Why?
|
Child | 133 | 2023 | 29154 | 0.970 |
Why?
|
T-Lymphocytes | 27 | 2021 | 3869 | 0.850 |
Why?
|
Leukemia | 19 | 2022 | 1635 | 0.830 |
Why?
|
Antibodies, Neoplasm | 6 | 2008 | 259 | 0.820 |
Why?
|
Tissue Donors | 12 | 2021 | 769 | 0.810 |
Why?
|
Granulomatous Disease, Chronic | 4 | 2018 | 79 | 0.780 |
Why?
|
Adolescent | 104 | 2022 | 31252 | 0.760 |
Why?
|
Cord Blood Stem Cell Transplantation | 1 | 2023 | 362 | 0.720 |
Why?
|
Antibodies, Monoclonal | 14 | 2008 | 4367 | 0.720 |
Why?
|
Infant | 56 | 2023 | 13310 | 0.710 |
Why?
|
Lymphoma, Non-Hodgkin | 3 | 2019 | 1039 | 0.700 |
Why?
|
Alemtuzumab | 9 | 2021 | 198 | 0.640 |
Why?
|
Hematologic Neoplasms | 10 | 2020 | 1870 | 0.620 |
Why?
|
Unrelated Donors | 5 | 2021 | 304 | 0.580 |
Why?
|
Lymphoma, Large-Cell, Anaplastic | 3 | 2018 | 387 | 0.550 |
Why?
|
Severe Combined Immunodeficiency | 5 | 2021 | 107 | 0.550 |
Why?
|
Immunotherapy, Adoptive | 13 | 2019 | 1763 | 0.530 |
Why?
|
Stem Cell Transplantation | 10 | 2017 | 1360 | 0.530 |
Why?
|
Immunologic Deficiency Syndromes | 4 | 2021 | 238 | 0.520 |
Why?
|
Lymphocyte Transfusion | 4 | 2021 | 175 | 0.510 |
Why?
|
Recurrence | 21 | 2023 | 4758 | 0.510 |
Why?
|
Anemia, Hemolytic, Autoimmune | 1 | 2015 | 46 | 0.500 |
Why?
|
T-Lymphocytes, Cytotoxic | 14 | 2014 | 1016 | 0.500 |
Why?
|
Leukocyte Common Antigens | 3 | 2005 | 188 | 0.500 |
Why?
|
Autoimmune Diseases | 4 | 2018 | 402 | 0.500 |
Why?
|
Herpesvirus 4, Human | 21 | 2023 | 966 | 0.480 |
Why?
|
Siblings | 3 | 2015 | 285 | 0.480 |
Why?
|
Epstein-Barr Virus Infections | 6 | 2023 | 489 | 0.480 |
Why?
|
Myeloablative Agonists | 2 | 2015 | 384 | 0.450 |
Why?
|
Humans | 186 | 2023 | 261506 | 0.440 |
Why?
|
Living Donors | 4 | 2008 | 171 | 0.440 |
Why?
|
Tumor Virus Infections | 6 | 2021 | 224 | 0.430 |
Why?
|
Hodgkin Disease | 5 | 2022 | 1429 | 0.420 |
Why?
|
Male | 111 | 2021 | 123000 | 0.420 |
Why?
|
Treatment Outcome | 36 | 2021 | 32848 | 0.420 |
Why?
|
Virus Diseases | 5 | 2023 | 398 | 0.400 |
Why?
|
Cystitis | 4 | 2021 | 107 | 0.390 |
Why?
|
Pyridines | 1 | 2018 | 1244 | 0.390 |
Why?
|
Whole-Body Irradiation | 12 | 2012 | 307 | 0.390 |
Why?
|
Lymphoproliferative Disorders | 7 | 2015 | 366 | 0.380 |
Why?
|
Female | 104 | 2021 | 141928 | 0.370 |
Why?
|
Anemia, Aplastic | 3 | 2006 | 214 | 0.370 |
Why?
|
BK Virus | 3 | 2021 | 123 | 0.360 |
Why?
|
Cytomegalovirus | 7 | 2019 | 482 | 0.350 |
Why?
|
Pyrazoles | 1 | 2018 | 1471 | 0.350 |
Why?
|
Young Adult | 21 | 2022 | 21445 | 0.340 |
Why?
|
Caspase 9 | 3 | 2015 | 189 | 0.340 |
Why?
|
Retrospective Studies | 30 | 2023 | 37905 | 0.330 |
Why?
|
Leukemia, Myeloid, Acute | 20 | 2021 | 6915 | 0.330 |
Why?
|
Polyomavirus Infections | 2 | 2021 | 139 | 0.320 |
Why?
|
Salvage Therapy | 3 | 2021 | 2054 | 0.310 |
Why?
|
Neuroblastoma | 9 | 2020 | 686 | 0.310 |
Why?
|
Graft vs Leukemia Effect | 2 | 2021 | 105 | 0.310 |
Why?
|
Immunocompromised Host | 8 | 2015 | 698 | 0.310 |
Why?
|
Donor Selection | 1 | 2008 | 110 | 0.310 |
Why?
|
Thrombotic Microangiopathies | 2 | 2019 | 70 | 0.310 |
Why?
|
Hematopoiesis | 3 | 2011 | 560 | 0.300 |
Why?
|
Genetic Markers | 12 | 1998 | 974 | 0.290 |
Why?
|
Cyclophosphamide | 13 | 2023 | 3001 | 0.290 |
Why?
|
Graft Rejection | 3 | 2015 | 834 | 0.280 |
Why?
|
Lymphohistiocytosis, Hemophagocytic | 2 | 2020 | 184 | 0.280 |
Why?
|
Bronchiolitis Obliterans | 2 | 2005 | 74 | 0.280 |
Why?
|
Translocation, Genetic | 6 | 2009 | 1245 | 0.280 |
Why?
|
Antilymphocyte Serum | 6 | 2006 | 228 | 0.270 |
Why?
|
Acute Disease | 17 | 2022 | 2422 | 0.270 |
Why?
|
DNA Viruses | 2 | 2017 | 48 | 0.260 |
Why?
|
Adult | 60 | 2023 | 77950 | 0.260 |
Why?
|
Adoptive Transfer | 3 | 2019 | 446 | 0.260 |
Why?
|
Herpesviridae Infections | 7 | 2013 | 175 | 0.250 |
Why?
|
Burkitt Lymphoma | 3 | 2023 | 335 | 0.250 |
Why?
|
Interleukin-1 Receptor-Like 1 Protein | 2 | 2023 | 30 | 0.240 |
Why?
|
Vidarabine | 2 | 2008 | 1341 | 0.240 |
Why?
|
Immunosuppressive Agents | 7 | 2015 | 1375 | 0.240 |
Why?
|
Prospective Studies | 11 | 2023 | 12873 | 0.240 |
Why?
|
Infant, Newborn | 13 | 2020 | 8223 | 0.240 |
Why?
|
Cell Phone | 2 | 2014 | 45 | 0.240 |
Why?
|
Antigens, CD19 | 2 | 2019 | 577 | 0.230 |
Why?
|
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 4 | 2023 | 482 | 0.230 |
Why?
|
Complement Activation | 1 | 2003 | 94 | 0.220 |
Why?
|
Transplantation, Autologous | 17 | 2022 | 1914 | 0.220 |
Why?
|
Protein Kinase Inhibitors | 1 | 2018 | 4757 | 0.220 |
Why?
|
Hepatic Veno-Occlusive Disease | 1 | 2023 | 122 | 0.210 |
Why?
|
Transplant Recipients | 3 | 2020 | 324 | 0.210 |
Why?
|
Immunoglobulins, Intravenous | 2 | 2023 | 180 | 0.210 |
Why?
|
Cytotoxicity, Immunologic | 3 | 2003 | 675 | 0.210 |
Why?
|
Interleukin-2 | 4 | 2014 | 842 | 0.200 |
Why?
|
Adenosine Deaminase | 2 | 2021 | 94 | 0.200 |
Why?
|
Agammaglobulinemia | 1 | 2021 | 46 | 0.200 |
Why?
|
Antiviral Agents | 3 | 2023 | 1230 | 0.200 |
Why?
|
Lymphocyte Depletion | 6 | 2012 | 264 | 0.190 |
Why?
|
Busulfan | 2 | 2023 | 764 | 0.190 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 22 | 2022 | 15862 | 0.190 |
Why?
|
Tumor Necrosis Factor-alpha | 2 | 2005 | 1538 | 0.190 |
Why?
|
Thiotepa | 2 | 2020 | 118 | 0.190 |
Why?
|
Respiratory Insufficiency | 2 | 2022 | 330 | 0.190 |
Why?
|
Leukemia, Myeloid | 10 | 2006 | 941 | 0.190 |
Why?
|
Survival Analysis | 9 | 2015 | 9180 | 0.180 |
Why?
|
Leukemia, Lymphoid | 7 | 1999 | 276 | 0.180 |
Why?
|
Antibodies, Bispecific | 1 | 2023 | 246 | 0.180 |
Why?
|
T-Lymphocyte Subsets | 3 | 2014 | 582 | 0.180 |
Why?
|
Cell- and Tissue-Based Therapy | 1 | 2023 | 406 | 0.180 |
Why?
|
Follow-Up Studies | 17 | 2020 | 14889 | 0.170 |
Why?
|
Biomarkers | 6 | 2023 | 5047 | 0.170 |
Why?
|
Antineoplastic Agents | 7 | 2013 | 14289 | 0.170 |
Why?
|
Biological Specimen Banks | 1 | 2019 | 76 | 0.170 |
Why?
|
Megakaryocyte Progenitor Cells | 1 | 2018 | 10 | 0.170 |
Why?
|
Lymphoma, B-Cell | 2 | 2019 | 895 | 0.170 |
Why?
|
Intercellular Signaling Peptides and Proteins | 2 | 2021 | 650 | 0.160 |
Why?
|
Twins, Monozygotic | 1 | 2018 | 129 | 0.160 |
Why?
|
Wiskott-Aldrich Syndrome | 1 | 2017 | 24 | 0.160 |
Why?
|
Remission Induction | 13 | 2017 | 3569 | 0.160 |
Why?
|
Graft Survival | 4 | 2015 | 1062 | 0.160 |
Why?
|
Infection Control | 2 | 2018 | 270 | 0.160 |
Why?
|
Epitopes | 2 | 2015 | 685 | 0.160 |
Why?
|
Antineoplastic Agents, Alkylating | 2 | 2020 | 588 | 0.150 |
Why?
|
Methotrexate | 9 | 2015 | 999 | 0.150 |
Why?
|
Anemia, Sickle Cell | 1 | 2021 | 339 | 0.150 |
Why?
|
DNA Virus Infections | 1 | 2017 | 29 | 0.150 |
Why?
|
Adenovirus Infections, Human | 2 | 2009 | 56 | 0.150 |
Why?
|
Organophosphonates | 1 | 2018 | 64 | 0.150 |
Why?
|
Survival Rate | 10 | 2020 | 12221 | 0.150 |
Why?
|
Plasma Exchange | 1 | 2018 | 117 | 0.150 |
Why?
|
Bone Marrow Purging | 7 | 2003 | 86 | 0.150 |
Why?
|
Histiocytes | 1 | 2017 | 94 | 0.150 |
Why?
|
Adenoviridae Infections | 2 | 2013 | 125 | 0.150 |
Why?
|
Xanthogranuloma, Juvenile | 1 | 2017 | 38 | 0.150 |
Why?
|
Histiocytosis, Langerhans-Cell | 2 | 2015 | 261 | 0.150 |
Why?
|
Cytosine | 1 | 2018 | 141 | 0.150 |
Why?
|
Vascular Resistance | 1 | 1997 | 200 | 0.150 |
Why?
|
Triazoles | 2 | 2011 | 617 | 0.150 |
Why?
|
Nurse's Role | 2 | 2014 | 42 | 0.150 |
Why?
|
Myeloid-Lymphoid Leukemia Protein | 1 | 2018 | 197 | 0.140 |
Why?
|
Ricin | 2 | 1994 | 34 | 0.140 |
Why?
|
Histocompatibility | 3 | 2006 | 168 | 0.140 |
Why?
|
Antifungal Agents | 3 | 2011 | 834 | 0.140 |
Why?
|
Hepatic Artery | 1 | 1997 | 240 | 0.140 |
Why?
|
Retinal Diseases | 1 | 2019 | 179 | 0.140 |
Why?
|
Mitogen-Activated Protein Kinase 1 | 1 | 2017 | 280 | 0.140 |
Why?
|
Methylprednisolone | 2 | 1995 | 193 | 0.140 |
Why?
|
Immunotoxins | 2 | 1994 | 117 | 0.140 |
Why?
|
Chromosomes, Human, Pair 6 | 1 | 1997 | 179 | 0.140 |
Why?
|
Chromosomes, Human, Pair 9 | 1 | 1997 | 290 | 0.140 |
Why?
|
Oncogene Proteins | 2 | 1997 | 354 | 0.140 |
Why?
|
Recombinant Fusion Proteins | 4 | 2014 | 1555 | 0.130 |
Why?
|
Genes, Transgenic, Suicide | 2 | 2015 | 69 | 0.130 |
Why?
|
Disease-Free Survival | 8 | 2017 | 10001 | 0.130 |
Why?
|
Adenoviridae | 6 | 2019 | 1459 | 0.130 |
Why?
|
Cardiac Tamponade | 1 | 1995 | 51 | 0.130 |
Why?
|
Cranial Irradiation | 2 | 2008 | 315 | 0.130 |
Why?
|
Leukemia, Promyelocytic, Acute | 3 | 2004 | 430 | 0.130 |
Why?
|
Receptors, Antigen, T-Cell | 2 | 2019 | 1146 | 0.130 |
Why?
|
Antibodies, Monoclonal, Humanized | 6 | 2008 | 3251 | 0.130 |
Why?
|
Histone-Lysine N-Methyltransferase | 1 | 2018 | 461 | 0.130 |
Why?
|
Glomerular Filtration Rate | 1 | 2018 | 602 | 0.130 |
Why?
|
Mucolipidoses | 1 | 2014 | 9 | 0.130 |
Why?
|
Phosphoglucomutase | 1 | 2014 | 9 | 0.130 |
Why?
|
Neuroectodermal Tumors, Primitive | 2 | 2008 | 100 | 0.120 |
Why?
|
Gene Transfer Techniques | 8 | 2011 | 716 | 0.120 |
Why?
|
Gene Rearrangement | 1 | 2018 | 783 | 0.120 |
Why?
|
Receptors, Fc | 1 | 2014 | 69 | 0.120 |
Why?
|
Leukocyte Count | 6 | 1996 | 684 | 0.120 |
Why?
|
Thrombopoietin | 1 | 2014 | 77 | 0.120 |
Why?
|
Podophyllotoxin | 2 | 1999 | 63 | 0.120 |
Why?
|
RNA, Neoplasm | 1 | 1997 | 771 | 0.120 |
Why?
|
Bone Diseases, Developmental | 1 | 2014 | 70 | 0.120 |
Why?
|
Cladribine | 2 | 1994 | 233 | 0.120 |
Why?
|
Epstein-Barr Virus Nuclear Antigens | 1 | 2014 | 71 | 0.120 |
Why?
|
Congenital Disorders of Glycosylation | 1 | 2014 | 37 | 0.120 |
Why?
|
Diarrhea | 2 | 2015 | 686 | 0.120 |
Why?
|
Micrococcaceae | 1 | 2013 | 4 | 0.120 |
Why?
|
Aspergillosis, Allergic Bronchopulmonary | 1 | 2013 | 34 | 0.120 |
Why?
|
Actinomycetales Infections | 1 | 2013 | 15 | 0.120 |
Why?
|
Myelodysplastic Syndromes | 5 | 2021 | 2979 | 0.120 |
Why?
|
Chronic Disease | 3 | 2015 | 1819 | 0.110 |
Why?
|
Dyskeratosis Congenita | 1 | 2013 | 26 | 0.110 |
Why?
|
Immune System | 1 | 2015 | 279 | 0.110 |
Why?
|
Portal Vein | 1 | 1995 | 355 | 0.110 |
Why?
|
Cytarabine | 11 | 2022 | 1973 | 0.110 |
Why?
|
Chromosomes, Human, Pair 17 | 2 | 1996 | 641 | 0.110 |
Why?
|
Lung Diseases | 2 | 1996 | 717 | 0.110 |
Why?
|
Allografts | 3 | 2021 | 650 | 0.110 |
Why?
|
Neomycin | 5 | 2000 | 38 | 0.110 |
Why?
|
Pseudotumor Cerebri | 1 | 1993 | 60 | 0.110 |
Why?
|
Incidence | 7 | 2018 | 5673 | 0.110 |
Why?
|
Viruses | 1 | 2014 | 159 | 0.110 |
Why?
|
Risk Factors | 13 | 2021 | 17523 | 0.110 |
Why?
|
Albumins | 1 | 2014 | 258 | 0.110 |
Why?
|
Systemic Inflammatory Response Syndrome | 1 | 2014 | 182 | 0.110 |
Why?
|
Organ Transplantation | 1 | 2015 | 191 | 0.110 |
Why?
|
Tacrolimus | 2 | 2006 | 335 | 0.110 |
Why?
|
Liver Diseases | 1 | 1997 | 574 | 0.110 |
Why?
|
Cytomegalovirus Infections | 3 | 2019 | 462 | 0.110 |
Why?
|
Caliciviridae Infections | 1 | 2015 | 279 | 0.110 |
Why?
|
Sibling Relations | 1 | 2011 | 13 | 0.100 |
Why?
|
Transgenes | 1 | 2014 | 557 | 0.100 |
Why?
|
B-Lymphocytes | 4 | 2013 | 1294 | 0.100 |
Why?
|
Antigens, CD | 4 | 2005 | 1385 | 0.100 |
Why?
|
Fetal Blood | 1 | 2015 | 482 | 0.100 |
Why?
|
Osteosarcoma | 2 | 2015 | 929 | 0.100 |
Why?
|
Self Care | 1 | 2013 | 224 | 0.100 |
Why?
|
Norovirus | 1 | 2015 | 287 | 0.100 |
Why?
|
Transplantation Chimera | 2 | 2008 | 155 | 0.100 |
Why?
|
Tacrolimus Binding Proteins | 1 | 2011 | 87 | 0.100 |
Why?
|
Information Dissemination | 1 | 2014 | 272 | 0.100 |
Why?
|
Chromosomes, Human, Pair 12 | 1 | 1992 | 185 | 0.100 |
Why?
|
Retroviridae | 5 | 2019 | 332 | 0.100 |
Why?
|
Tretinoin | 1 | 1993 | 623 | 0.100 |
Why?
|
Risk | 2 | 2015 | 1972 | 0.100 |
Why?
|
Karyotyping | 6 | 2009 | 1022 | 0.100 |
Why?
|
Proteome | 1 | 2014 | 561 | 0.090 |
Why?
|
Aziridines | 1 | 1990 | 17 | 0.090 |
Why?
|
Immunomodulation | 1 | 2012 | 242 | 0.090 |
Why?
|
Immunophenotyping | 9 | 2014 | 1681 | 0.090 |
Why?
|
Thrombocytopenia | 2 | 2014 | 846 | 0.090 |
Why?
|
Educational Status | 1 | 2011 | 397 | 0.090 |
Why?
|
Combined Modality Therapy | 13 | 2021 | 8865 | 0.090 |
Why?
|
Bone Marrow Cells | 5 | 2005 | 943 | 0.090 |
Why?
|
Benzoquinones | 1 | 1990 | 108 | 0.090 |
Why?
|
Infusions, Intravenous | 6 | 2011 | 1382 | 0.090 |
Why?
|
Liver Function Tests | 3 | 2011 | 173 | 0.090 |
Why?
|
Genetic Testing | 1 | 2018 | 1589 | 0.090 |
Why?
|
T-Lymphocytes, Regulatory | 1 | 2014 | 673 | 0.090 |
Why?
|
Antigens, Neoplasm | 3 | 2021 | 1506 | 0.090 |
Why?
|
Genome, Human | 1 | 2018 | 1869 | 0.090 |
Why?
|
Organic Chemicals | 3 | 2015 | 113 | 0.090 |
Why?
|
Renal Insufficiency, Chronic | 1 | 2018 | 787 | 0.090 |
Why?
|
Hematopoietic Stem Cells | 7 | 1996 | 1242 | 0.090 |
Why?
|
Prognosis | 11 | 2020 | 21713 | 0.090 |
Why?
|
Rotavirus Infections | 1 | 2011 | 287 | 0.080 |
Why?
|
Pyrimidines | 2 | 2011 | 3518 | 0.080 |
Why?
|
High-Throughput Nucleotide Sequencing | 1 | 2018 | 2291 | 0.080 |
Why?
|
Peroxidase | 1 | 2009 | 132 | 0.080 |
Why?
|
Medulloblastoma | 2 | 2006 | 540 | 0.080 |
Why?
|
National Health Programs | 1 | 2008 | 42 | 0.080 |
Why?
|
Activities of Daily Living | 1 | 2011 | 552 | 0.080 |
Why?
|
Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 4 | 2000 | 2527 | 0.080 |
Why?
|
Aspergillosis | 2 | 2014 | 246 | 0.080 |
Why?
|
Supratentorial Neoplasms | 1 | 2008 | 78 | 0.080 |
Why?
|
Multiple Sclerosis | 3 | 2004 | 349 | 0.080 |
Why?
|
Pilot Projects | 6 | 2020 | 2803 | 0.080 |
Why?
|
Teniposide | 1 | 1987 | 4 | 0.080 |
Why?
|
Kinetics | 1 | 2011 | 2049 | 0.080 |
Why?
|
Hospitals | 2 | 2021 | 485 | 0.080 |
Why?
|
Brain Neoplasms | 4 | 2008 | 4849 | 0.080 |
Why?
|
Age Factors | 6 | 2020 | 5377 | 0.080 |
Why?
|
Randomized Controlled Trials as Topic | 2 | 2006 | 2594 | 0.080 |
Why?
|
Proteomics | 1 | 2014 | 1380 | 0.070 |
Why?
|
Lymph Nodes | 3 | 2017 | 2967 | 0.070 |
Why?
|
Texas | 4 | 2021 | 6311 | 0.070 |
Why?
|
Metabolic Diseases | 1 | 2008 | 130 | 0.070 |
Why?
|
Dose-Response Relationship, Immunologic | 2 | 2006 | 182 | 0.070 |
Why?
|
RNA, Messenger | 1 | 1997 | 6150 | 0.070 |
Why?
|
Kaplan-Meier Estimate | 3 | 2021 | 6207 | 0.070 |
Why?
|
Myelin Basic Protein | 2 | 2004 | 85 | 0.070 |
Why?
|
Neoplasm Recurrence, Local | 4 | 2022 | 10035 | 0.070 |
Why?
|
Genetic Vectors | 5 | 2019 | 1694 | 0.070 |
Why?
|
Immunoglobulin G | 3 | 2018 | 1021 | 0.070 |
Why?
|
Bone Neoplasms | 2 | 2015 | 2576 | 0.070 |
Why?
|
RNA, Viral | 2 | 2022 | 671 | 0.070 |
Why?
|
Immune System Diseases | 1 | 2006 | 65 | 0.070 |
Why?
|
Melphalan | 2 | 2022 | 834 | 0.070 |
Why?
|
Philadelphia Chromosome | 2 | 2008 | 793 | 0.070 |
Why?
|
Transcription Factors | 3 | 2009 | 5270 | 0.070 |
Why?
|
Mutation | 2 | 2017 | 15179 | 0.070 |
Why?
|
Haplotypes | 3 | 2015 | 856 | 0.070 |
Why?
|
Cost-Benefit Analysis | 1 | 2010 | 945 | 0.070 |
Why?
|
Cyclosporine | 1 | 2006 | 278 | 0.070 |
Why?
|
Hemolytic-Uremic Syndrome | 1 | 2005 | 69 | 0.070 |
Why?
|
CD40 Ligand | 1 | 2005 | 115 | 0.070 |
Why?
|
Infliximab | 1 | 2005 | 130 | 0.060 |
Why?
|
Clinical Trials as Topic | 2 | 2010 | 3719 | 0.060 |
Why?
|
Mucopolysaccharidosis I | 1 | 2004 | 7 | 0.060 |
Why?
|
Lymphocyte Count | 3 | 2014 | 486 | 0.060 |
Why?
|
Syndactyly | 1 | 2005 | 26 | 0.060 |
Why?
|
Cell Division | 4 | 2004 | 2489 | 0.060 |
Why?
|
Feasibility Studies | 5 | 2014 | 2292 | 0.060 |
Why?
|
Laryngeal Diseases | 1 | 2004 | 49 | 0.060 |
Why?
|
Bone Marrow | 7 | 2018 | 2358 | 0.060 |
Why?
|
Middle Aged | 16 | 2022 | 86204 | 0.060 |
Why?
|
Induction Chemotherapy | 2 | 2020 | 669 | 0.060 |
Why?
|
Gene Rearrangement, beta-Chain T-Cell Antigen Receptor | 1 | 2004 | 33 | 0.060 |
Why?
|
Virus Activation | 4 | 2005 | 228 | 0.060 |
Why?
|
Lymphoma | 5 | 2000 | 1467 | 0.060 |
Why?
|
Comorbidity | 1 | 2011 | 2352 | 0.060 |
Why?
|
Lymphocytes | 3 | 2006 | 1234 | 0.060 |
Why?
|
Leukemia-Lymphoma, Adult T-Cell | 2 | 1995 | 65 | 0.060 |
Why?
|
Chromosomes, Human, Pair 7 | 1 | 2005 | 234 | 0.060 |
Why?
|
Prednisone | 6 | 2014 | 984 | 0.060 |
Why?
|
Hydroxyurea | 1 | 2004 | 204 | 0.060 |
Why?
|
HLA Antigens | 2 | 2019 | 546 | 0.060 |
Why?
|
Cell Culture Techniques | 1 | 2006 | 598 | 0.060 |
Why?
|
Chromosome Aberrations | 4 | 2018 | 1960 | 0.060 |
Why?
|
Cisplatin | 4 | 2015 | 2432 | 0.060 |
Why?
|
Dose-Response Relationship, Drug | 5 | 2014 | 4938 | 0.060 |
Why?
|
Hemorrhagic Disorders | 1 | 2003 | 51 | 0.060 |
Why?
|
Adenoviruses, Human | 2 | 2017 | 181 | 0.060 |
Why?
|
Neutropenia | 2 | 1991 | 968 | 0.060 |
Why?
|
Cells, Cultured | 6 | 2017 | 5637 | 0.060 |
Why?
|
Pharmacokinetics | 1 | 2003 | 42 | 0.060 |
Why?
|
Phosphotransferases (Alcohol Group Acceptor) | 2 | 1994 | 129 | 0.060 |
Why?
|
Abscess | 1 | 2004 | 177 | 0.060 |
Why?
|
Laryngectomy | 1 | 2004 | 242 | 0.060 |
Why?
|
Drug Administration Schedule | 6 | 2011 | 3472 | 0.060 |
Why?
|
Aspergillus fumigatus | 2 | 2014 | 135 | 0.060 |
Why?
|
Agranulocytosis | 1 | 1982 | 79 | 0.060 |
Why?
|
Leukemia, Megakaryoblastic, Acute | 1 | 1993 | 47 | 0.060 |
Why?
|
Myositis Ossificans | 1 | 1983 | 30 | 0.060 |
Why?
|
United States | 5 | 2013 | 15433 | 0.060 |
Why?
|
Antigens, Differentiation | 2 | 1995 | 238 | 0.060 |
Why?
|
CD4-Positive T-Lymphocytes | 2 | 2006 | 1033 | 0.060 |
Why?
|
Etoposide | 4 | 2014 | 870 | 0.060 |
Why?
|
Hematologic Diseases | 4 | 2014 | 242 | 0.050 |
Why?
|
Periodicity | 1 | 1982 | 68 | 0.050 |
Why?
|
Cohort Studies | 5 | 2018 | 9244 | 0.050 |
Why?
|
Autoantigens | 1 | 2004 | 234 | 0.050 |
Why?
|
Genetic Therapy | 2 | 2000 | 1616 | 0.050 |
Why?
|
DNA, Viral | 5 | 2009 | 694 | 0.050 |
Why?
|
Recovery of Function | 1 | 2005 | 703 | 0.050 |
Why?
|
Cytochrome P-450 CYP2C19 | 2 | 2011 | 22 | 0.050 |
Why?
|
Cerebellar Neoplasms | 1 | 2006 | 434 | 0.050 |
Why?
|
Carmustine | 1 | 2022 | 214 | 0.050 |
Why?
|
Models, Animal | 1 | 2004 | 664 | 0.050 |
Why?
|
Glycoproteins | 1 | 2005 | 747 | 0.050 |
Why?
|
Aryl Hydrocarbon Hydroxylases | 2 | 2011 | 78 | 0.050 |
Why?
|
Myeloid Cells | 1 | 2003 | 269 | 0.050 |
Why?
|
T-Cell Antigen Receptor Specificity | 1 | 2021 | 107 | 0.050 |
Why?
|
Voriconazole | 2 | 2011 | 108 | 0.050 |
Why?
|
Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2013 | 2390 | 0.050 |
Why?
|
Biomarkers, Tumor | 1 | 2020 | 10331 | 0.050 |
Why?
|
Chemokines, C | 1 | 2000 | 10 | 0.050 |
Why?
|
Flow Cytometry | 4 | 2015 | 3033 | 0.050 |
Why?
|
CD8-Positive T-Lymphocytes | 2 | 2006 | 1586 | 0.050 |
Why?
|
Cytokines | 3 | 2021 | 2809 | 0.050 |
Why?
|
Administration, Oral | 3 | 2011 | 1544 | 0.050 |
Why?
|
Interferon Type I | 1 | 2021 | 250 | 0.050 |
Why?
|
Quality of Life | 2 | 2011 | 4532 | 0.050 |
Why?
|
Sialoglycoproteins | 1 | 2000 | 151 | 0.050 |
Why?
|
Cell Line | 5 | 2013 | 5114 | 0.050 |
Why?
|
Chromosome Deletion | 1 | 2005 | 1005 | 0.050 |
Why?
|
Monitoring, Immunologic | 1 | 2020 | 47 | 0.050 |
Why?
|
Cancer Vaccines | 1 | 2005 | 697 | 0.040 |
Why?
|
Maximum Tolerated Dose | 1 | 2003 | 1290 | 0.040 |
Why?
|
Lymphokines | 1 | 2000 | 272 | 0.040 |
Why?
|
Polymerase Chain Reaction | 6 | 2009 | 3203 | 0.040 |
Why?
|
Tissue Banks | 1 | 2019 | 55 | 0.040 |
Why?
|
Rituximab | 2 | 2022 | 1528 | 0.040 |
Why?
|
Viral Load | 2 | 2016 | 493 | 0.040 |
Why?
|
Histocompatibility Testing | 3 | 2009 | 447 | 0.040 |
Why?
|
Time Factors | 8 | 2014 | 12926 | 0.040 |
Why?
|
Drug Evaluation | 5 | 1990 | 425 | 0.040 |
Why?
|
Aged | 7 | 2022 | 70117 | 0.040 |
Why?
|
Postoperative Complications | 4 | 2014 | 5542 | 0.040 |
Why?
|
Chimerism | 1 | 2018 | 63 | 0.040 |
Why?
|
Antigens, Viral | 2 | 2013 | 471 | 0.040 |
Why?
|
Guillain-Barre Syndrome | 1 | 2018 | 35 | 0.040 |
Why?
|
Doxorubicin | 2 | 2015 | 3005 | 0.040 |
Why?
|
Neoplasms | 7 | 2014 | 15193 | 0.040 |
Why?
|
Administration, Intravesical | 1 | 2018 | 162 | 0.040 |
Why?
|
Pancytopenia | 1 | 2018 | 120 | 0.040 |
Why?
|
Multifactorial Inheritance | 1 | 2018 | 148 | 0.040 |
Why?
|
XYY Karyotype | 1 | 1997 | 2 | 0.040 |
Why?
|
Nerve Tissue Proteins | 1 | 2005 | 1491 | 0.040 |
Why?
|
Herpesvirus 6, Human | 1 | 2017 | 81 | 0.040 |
Why?
|
Ultrasonography, Doppler | 1 | 1997 | 231 | 0.040 |
Why?
|
Data Collection | 2 | 2014 | 620 | 0.040 |
Why?
|
Drug Therapy | 1 | 2017 | 205 | 0.040 |
Why?
|
Chimera | 1 | 1996 | 145 | 0.030 |
Why?
|
Energy Metabolism | 1 | 2002 | 992 | 0.030 |
Why?
|
Ultrasonography, Doppler, Pulsed | 1 | 1995 | 17 | 0.030 |
Why?
|
History, 21st Century | 1 | 2018 | 441 | 0.030 |
Why?
|
Membrane Lipids | 1 | 1995 | 48 | 0.030 |
Why?
|
Tomography, X-Ray Computed | 3 | 2004 | 7551 | 0.030 |
Why?
|
Immunologic Memory | 2 | 2009 | 374 | 0.030 |
Why?
|
Glycolipids | 1 | 1995 | 58 | 0.030 |
Why?
|
Adrenal Cortex Hormones | 2 | 2014 | 544 | 0.030 |
Why?
|
Lupus Erythematosus, Systemic | 1 | 1998 | 223 | 0.030 |
Why?
|
Gene Expression | 2 | 2014 | 3570 | 0.030 |
Why?
|
Pedigree | 2 | 2014 | 1890 | 0.030 |
Why?
|
Femoral Neoplasms | 1 | 2015 | 64 | 0.030 |
Why?
|
Injections, Intravenous | 2 | 2011 | 573 | 0.030 |
Why?
|
Vincristine | 4 | 2008 | 1511 | 0.030 |
Why?
|
Chromosomes, Human, Pair 15 | 1 | 1996 | 231 | 0.030 |
Why?
|
Receptors, Antigen, T-Cell, gamma-delta | 1 | 1996 | 166 | 0.030 |
Why?
|
Drug Resistance | 4 | 2001 | 587 | 0.030 |
Why?
|
Receptors, Retinoic Acid | 1 | 1996 | 365 | 0.030 |
Why?
|
3-Iodobenzylguanidine | 1 | 2014 | 31 | 0.030 |
Why?
|
Mycoplasma Infections | 1 | 1994 | 16 | 0.030 |
Why?
|
Anorexia | 1 | 1995 | 143 | 0.030 |
Why?
|
Mesna | 1 | 1994 | 65 | 0.030 |
Why?
|
Chromosomes, Human, Pair 11 | 1 | 1996 | 402 | 0.030 |
Why?
|
Immunoglobulin M | 1 | 1995 | 347 | 0.030 |
Why?
|
Pulmonary Edema | 1 | 1994 | 80 | 0.030 |
Why?
|
Etanercept | 1 | 2014 | 54 | 0.030 |
Why?
|
Biopsy | 3 | 2018 | 3443 | 0.030 |
Why?
|
Blast Crisis | 2 | 1994 | 557 | 0.030 |
Why?
|
Rats | 1 | 2003 | 6086 | 0.030 |
Why?
|
Enzyme Induction | 1 | 2014 | 249 | 0.030 |
Why?
|
Blood Flow Velocity | 1 | 1995 | 475 | 0.030 |
Why?
|
Pediatric Nursing | 1 | 2014 | 38 | 0.030 |
Why?
|
Consolidation Chemotherapy | 1 | 2014 | 155 | 0.030 |
Why?
|
Immunotherapy | 2 | 2014 | 3341 | 0.030 |
Why?
|
NADPH Oxidase 2 | 1 | 2013 | 47 | 0.030 |
Why?
|
Neoplasm Grading | 1 | 2018 | 1742 | 0.030 |
Why?
|
Hemorrhage | 2 | 1999 | 712 | 0.030 |
Why?
|
Receptors, Tumor Necrosis Factor | 1 | 2014 | 184 | 0.030 |
Why?
|
Animals | 7 | 2013 | 59536 | 0.030 |
Why?
|
Protein Engineering | 1 | 2013 | 100 | 0.030 |
Why?
|
Genotype | 2 | 2011 | 4109 | 0.030 |
Why?
|
Proportional Hazards Models | 1 | 2022 | 4988 | 0.030 |
Why?
|
Multivariate Analysis | 3 | 2011 | 4298 | 0.030 |
Why?
|
Radionuclide Imaging | 1 | 2014 | 660 | 0.030 |
Why?
|
Bone Diseases | 1 | 1994 | 143 | 0.030 |
Why?
|
NADPH Oxidases | 1 | 2013 | 146 | 0.030 |
Why?
|
Enteral Nutrition | 1 | 1995 | 316 | 0.030 |
Why?
|
Species Specificity | 1 | 2014 | 777 | 0.030 |
Why?
|
HLA-DR Antigens | 1 | 1992 | 173 | 0.030 |
Why?
|
Cyclosporins | 3 | 1987 | 112 | 0.030 |
Why?
|
Granulocyte Precursor Cells | 1 | 2012 | 37 | 0.030 |
Why?
|
Chromosomes, Human, Pair 21 | 1 | 1992 | 104 | 0.030 |
Why?
|
Neprilysin | 1 | 1992 | 66 | 0.030 |
Why?
|
Th1 Cells | 1 | 2013 | 250 | 0.030 |
Why?
|
Stem Cells | 2 | 2014 | 1213 | 0.030 |
Why?
|
Antigens, Differentiation, Myelomonocytic | 1 | 1992 | 134 | 0.030 |
Why?
|
Sialic Acid Binding Ig-like Lectin 3 | 1 | 1992 | 83 | 0.030 |
Why?
|
Gentamicins | 1 | 1992 | 90 | 0.030 |
Why?
|
Aging | 1 | 2000 | 1582 | 0.030 |
Why?
|
Lung Diseases, Interstitial | 1 | 1994 | 199 | 0.030 |
Why?
|
DNA-Binding Proteins | 1 | 2005 | 4821 | 0.030 |
Why?
|
Oncogene Proteins, Fusion | 1 | 1997 | 755 | 0.030 |
Why?
|
Leukocytes | 1 | 1993 | 422 | 0.030 |
Why?
|
Chromosomes, Human, Pair 8 | 1 | 1992 | 317 | 0.030 |
Why?
|
Feces | 1 | 2015 | 770 | 0.030 |
Why?
|
Phenotype | 2 | 2017 | 6295 | 0.020 |
Why?
|
Carboplatin | 1 | 2014 | 823 | 0.020 |
Why?
|
Real-Time Polymerase Chain Reaction | 1 | 2015 | 1217 | 0.020 |
Why?
|
Cell Proliferation | 2 | 2014 | 7226 | 0.020 |
Why?
|
Killer Cells, Natural | 2 | 1995 | 904 | 0.020 |
Why?
|
Brain | 1 | 2004 | 4113 | 0.020 |
Why?
|
Sex Factors | 1 | 1996 | 2139 | 0.020 |
Why?
|
Life Tables | 2 | 1997 | 120 | 0.020 |
Why?
|
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2014 | 305 | 0.020 |
Why?
|
Basic Helix-Loop-Helix Transcription Factors | 1 | 2014 | 622 | 0.020 |
Why?
|
Drug Resistance, Microbial | 3 | 1998 | 218 | 0.020 |
Why?
|
Anti-Inflammatory Agents | 1 | 2014 | 461 | 0.020 |
Why?
|
Syndrome | 1 | 1993 | 1351 | 0.020 |
Why?
|
Astrocytoma | 1 | 1992 | 321 | 0.020 |
Why?
|
Wilms Tumor | 1 | 1992 | 292 | 0.020 |
Why?
|
Respiratory Tract Infections | 1 | 1994 | 437 | 0.020 |
Why?
|
Echocardiography | 1 | 1995 | 1182 | 0.020 |
Why?
|
Kanamycin Kinase | 3 | 1994 | 18 | 0.020 |
Why?
|
Platelet Count | 1 | 1991 | 490 | 0.020 |
Why?
|
Delayed Diagnosis | 1 | 2011 | 144 | 0.020 |
Why?
|
Genome-Wide Association Study | 1 | 2018 | 2265 | 0.020 |
Why?
|
Mice | 4 | 2013 | 34495 | 0.020 |
Why?
|
Gene Deletion | 1 | 2014 | 1442 | 0.020 |
Why?
|
Body Weight | 1 | 2014 | 1293 | 0.020 |
Why?
|
Chemical and Drug Induced Liver Injury | 1 | 1991 | 193 | 0.020 |
Why?
|
Sensitivity and Specificity | 1 | 1997 | 4971 | 0.020 |
Why?
|
Immunoglobulin A | 1 | 2009 | 237 | 0.020 |
Why?
|
Radiopharmaceuticals | 1 | 2014 | 1301 | 0.020 |
Why?
|
Chromosome Breakage | 1 | 2009 | 226 | 0.020 |
Why?
|
Protein-Tyrosine Kinases | 1 | 1996 | 1756 | 0.020 |
Why?
|
Membrane Glycoproteins | 1 | 2013 | 1073 | 0.020 |
Why?
|
Neoplasm, Residual | 1 | 2014 | 1656 | 0.020 |
Why?
|
Central Nervous System Neoplasms | 1 | 1993 | 502 | 0.020 |
Why?
|
Isoantibodies | 2 | 1986 | 115 | 0.020 |
Why?
|
Zinc Fingers | 1 | 2009 | 205 | 0.020 |
Why?
|
Clinical Protocols | 3 | 1996 | 467 | 0.020 |
Why?
|
Safety | 3 | 1994 | 465 | 0.020 |
Why?
|
Fever | 1 | 1991 | 497 | 0.020 |
Why?
|
Patient Satisfaction | 1 | 2013 | 915 | 0.020 |
Why?
|
Mercaptopurine | 3 | 1995 | 130 | 0.020 |
Why?
|
Chemotherapy, Adjuvant | 1 | 2015 | 3890 | 0.020 |
Why?
|
Chromosome Mapping | 2 | 2005 | 1471 | 0.020 |
Why?
|
Gamma Rays | 1 | 2008 | 242 | 0.020 |
Why?
|
Disease Models, Animal | 2 | 1998 | 7222 | 0.020 |
Why?
|
Proto-Oncogene Proteins | 1 | 1996 | 2488 | 0.020 |
Why?
|
Dose-Response Relationship, Radiation | 1 | 2008 | 726 | 0.020 |
Why?
|
Transfection | 1 | 1992 | 2944 | 0.020 |
Why?
|
Neoplasms, Second Primary | 1 | 1995 | 1350 | 0.020 |
Why?
|
Protein Array Analysis | 1 | 2009 | 501 | 0.020 |
Why?
|
Radiation Injuries | 1 | 1994 | 1411 | 0.020 |
Why?
|
Drug Resistance, Neoplasm | 1 | 2000 | 5178 | 0.020 |
Why?
|
Body Mass Index | 1 | 2014 | 2203 | 0.020 |
Why?
|
Anthraquinones | 1 | 1986 | 27 | 0.020 |
Why?
|
Major Histocompatibility Complex | 1 | 2006 | 91 | 0.020 |
Why?
|
Electronic Health Records | 1 | 2014 | 929 | 0.020 |
Why?
|
Daunorubicin | 3 | 1995 | 301 | 0.020 |
Why?
|
CD52 Antigen | 1 | 2005 | 46 | 0.020 |
Why?
|
Hemolysis | 1 | 1986 | 127 | 0.020 |
Why?
|
Anti-Bacterial Agents | 1 | 1998 | 2992 | 0.020 |
Why?
|
Zinc Finger Protein Gli3 | 1 | 2005 | 12 | 0.020 |
Why?
|
Nuclear Proteins | 1 | 1996 | 3343 | 0.020 |
Why?
|
Ikaros Transcription Factor | 1 | 2005 | 54 | 0.020 |
Why?
|
Pneumonia | 1 | 1991 | 751 | 0.020 |
Why?
|
T-Lymphocytes, Helper-Inducer | 1 | 2005 | 212 | 0.020 |
Why?
|
Erythrocytes | 1 | 1986 | 339 | 0.020 |
Why?
|
Neoplasm Proteins | 1 | 1996 | 3230 | 0.020 |
Why?
|
Registries | 1 | 2012 | 2170 | 0.020 |
Why?
|
Base Sequence | 3 | 1996 | 4917 | 0.020 |
Why?
|
Genes, Immunoglobulin | 1 | 2004 | 87 | 0.020 |
Why?
|
Length of Stay | 1 | 1991 | 1900 | 0.010 |
Why?
|
Mice, Knockout | 1 | 2013 | 5710 | 0.010 |
Why?
|
In Situ Hybridization, Fluorescence | 1 | 2009 | 2232 | 0.010 |
Why?
|
Age Distribution | 1 | 2005 | 698 | 0.010 |
Why?
|
Molecular Sequence Data | 3 | 1996 | 6089 | 0.010 |
Why?
|
Immunoglobulin Variable Region | 1 | 2004 | 173 | 0.010 |
Why?
|
Asparaginase | 2 | 1995 | 184 | 0.010 |
Why?
|
DNA Mutational Analysis | 1 | 2009 | 2283 | 0.010 |
Why?
|
Brazil | 1 | 1993 | 165 | 0.010 |
Why?
|
Kruppel-Like Transcription Factors | 1 | 2005 | 270 | 0.010 |
Why?
|
Oligonucleotide Array Sequence Analysis | 1 | 2009 | 2508 | 0.010 |
Why?
|
Calorimetry, Indirect | 1 | 2002 | 60 | 0.010 |
Why?
|
Thymus Gland | 1 | 2004 | 294 | 0.010 |
Why?
|
Mice, Inbred C57BL | 1 | 2013 | 6942 | 0.010 |
Why?
|
Sarcoma | 1 | 1992 | 1725 | 0.010 |
Why?
|
Glioma | 1 | 1993 | 1963 | 0.010 |
Why?
|
Surveys and Questionnaires | 1 | 2014 | 5687 | 0.010 |
Why?
|
Promoter Regions, Genetic | 1 | 2009 | 3101 | 0.010 |
Why?
|
Horses | 1 | 2001 | 96 | 0.010 |
Why?
|
Interleukin-10 | 1 | 2004 | 478 | 0.010 |
Why?
|
Neoplastic Stem Cells | 2 | 1994 | 1443 | 0.010 |
Why?
|
Dogs | 1 | 1982 | 1155 | 0.010 |
Why?
|
Pediatrics | 1 | 1990 | 1141 | 0.010 |
Why?
|
Informed Consent | 2 | 1994 | 419 | 0.010 |
Why?
|
Down Syndrome | 1 | 1993 | 226 | 0.010 |
Why?
|
Evaluation Studies as Topic | 2 | 1994 | 418 | 0.010 |
Why?
|
Topotecan | 1 | 2001 | 239 | 0.010 |
Why?
|
Leukemia L1210 | 1 | 1980 | 54 | 0.010 |
Why?
|
Myeloproliferative Disorders | 1 | 1987 | 767 | 0.010 |
Why?
|
Rabbits | 1 | 2001 | 957 | 0.010 |
Why?
|
Nutritional Status | 1 | 2002 | 337 | 0.010 |
Why?
|
Interferon-gamma | 1 | 2004 | 1144 | 0.010 |
Why?
|
Drug Synergism | 2 | 1995 | 1313 | 0.010 |
Why?
|
Family | 1 | 2003 | 736 | 0.010 |
Why?
|
Energy Intake | 1 | 2002 | 515 | 0.010 |
Why?
|
Antigens, CD20 | 1 | 2000 | 206 | 0.010 |
Why?
|
Signal Transduction | 1 | 2017 | 11965 | 0.010 |
Why?
|
Transduction, Genetic | 1 | 2000 | 475 | 0.010 |
Why?
|
Central Nervous System Diseases | 2 | 1994 | 129 | 0.010 |
Why?
|
Genes, Viral | 1 | 1998 | 202 | 0.010 |
Why?
|
Models, Theoretical | 1 | 2002 | 785 | 0.010 |
Why?
|
Fibroblasts | 1 | 2005 | 1682 | 0.010 |
Why?
|
Liver Failure | 1 | 1999 | 140 | 0.010 |
Why?
|
Blood Transfusion | 1 | 2001 | 583 | 0.010 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 1 | 2004 | 3639 | 0.010 |
Why?
|
Apoptosis | 1 | 2011 | 7591 | 0.010 |
Why?
|
Antibodies, Monoclonal, Murine-Derived | 1 | 2000 | 864 | 0.010 |
Why?
|
Promyelocytic Leukemia Protein | 1 | 1996 | 55 | 0.010 |
Why?
|
Retinoic Acid Receptor alpha | 1 | 1996 | 95 | 0.010 |
Why?
|
Oligonucleotide Probes | 1 | 1996 | 130 | 0.010 |
Why?
|
S Phase | 1 | 1997 | 281 | 0.010 |
Why?
|
Proto-Oncogene Proteins c-bcr | 1 | 1996 | 64 | 0.010 |
Why?
|
Genes, abl | 1 | 1996 | 110 | 0.010 |
Why?
|
Global Health | 1 | 2001 | 657 | 0.010 |
Why?
|
Chromosome Inversion | 1 | 1997 | 182 | 0.010 |
Why?
|
Nuclear Family | 1 | 1996 | 55 | 0.010 |
Why?
|
Gastroenteritis | 1 | 1999 | 300 | 0.010 |
Why?
|
Arm | 1 | 1996 | 147 | 0.010 |
Why?
|
Cell Count | 1 | 1997 | 508 | 0.010 |
Why?
|
Transplantation Immunology | 1 | 1995 | 97 | 0.010 |
Why?
|
Leg | 1 | 1996 | 226 | 0.010 |
Why?
|
Disease Progression | 1 | 2006 | 6682 | 0.010 |
Why?
|
Nervous System Diseases | 1 | 1980 | 500 | 0.010 |
Why?
|
Introns | 1 | 1996 | 432 | 0.010 |
Why?
|
Blood Platelets | 1 | 1980 | 731 | 0.010 |
Why?
|
Social Adjustment | 1 | 1995 | 114 | 0.010 |
Why?
|
Mycoplasma | 1 | 1994 | 14 | 0.010 |
Why?
|
Intelligence | 1 | 1995 | 126 | 0.010 |
Why?
|
Cell Transformation, Viral | 1 | 1995 | 138 | 0.010 |
Why?
|
Blotting, Southern | 1 | 1995 | 406 | 0.010 |
Why?
|
Moloney murine leukemia virus | 1 | 1994 | 23 | 0.010 |
Why?
|
Osteochondroma | 1 | 1994 | 12 | 0.010 |
Why?
|
Antigens, CD34 | 1 | 1996 | 593 | 0.010 |
Why?
|
Tumor Stem Cell Assay | 1 | 1994 | 231 | 0.010 |
Why?
|
Leukemic Infiltration | 1 | 1994 | 72 | 0.010 |
Why?
|
Granulocyte Colony-Stimulating Factor | 1 | 1997 | 749 | 0.010 |
Why?
|
Lymphocyte Subsets | 1 | 1994 | 137 | 0.010 |
Why?
|
DNA Primers | 1 | 1996 | 1399 | 0.010 |
Why?
|
Gastrostomy | 1 | 1995 | 180 | 0.010 |
Why?
|
CD5 Antigens | 1 | 1994 | 112 | 0.010 |
Why?
|
Lung | 3 | 1994 | 3151 | 0.010 |
Why?
|
Cell Survival | 2 | 1996 | 3045 | 0.010 |
Why?
|
Pharynx | 1 | 1994 | 153 | 0.010 |
Why?
|
Self Concept | 1 | 1995 | 211 | 0.010 |
Why?
|
Bronchoalveolar Lavage Fluid | 1 | 1994 | 254 | 0.010 |
Why?
|
Gene Expression Regulation, Neoplastic | 1 | 2009 | 8873 | 0.010 |
Why?
|
Cerebrospinal Fluid | 1 | 1993 | 120 | 0.010 |
Why?
|
Clone Cells | 1 | 1994 | 555 | 0.010 |
Why?
|
Tumor Cells, Cultured | 1 | 2000 | 5395 | 0.010 |
Why?
|
Chromosome Banding | 1 | 1992 | 256 | 0.010 |
Why?
|
Exons | 1 | 1996 | 1328 | 0.010 |
Why?
|
Forecasting | 1 | 1995 | 694 | 0.010 |
Why?
|
Amsacrine | 1 | 1992 | 61 | 0.010 |
Why?
|
Phosphotransferases | 1 | 1992 | 84 | 0.010 |
Why?
|
Mycoses | 1 | 1996 | 386 | 0.010 |
Why?
|
Colony-Forming Units Assay | 1 | 1992 | 249 | 0.010 |
Why?
|
Cell Separation | 1 | 1994 | 612 | 0.010 |
Why?
|
Bacterial Infections | 1 | 1996 | 479 | 0.010 |
Why?
|
Deoxyadenosines | 1 | 1992 | 42 | 0.010 |
Why?
|
2-Chloroadenosine | 1 | 1992 | 37 | 0.010 |
Why?
|
Recombinant Proteins | 1 | 1997 | 2927 | 0.010 |
Why?
|
Drug Therapy, Combination | 2 | 1987 | 2315 | 0.010 |
Why?
|
Neoplasms, Radiation-Induced | 1 | 1994 | 388 | 0.010 |
Why?
|
Cause of Death | 1 | 1994 | 752 | 0.010 |
Why?
|
Practice Guidelines as Topic | 1 | 2001 | 2403 | 0.010 |
Why?
|
Receptors, Immunologic | 1 | 1993 | 309 | 0.010 |
Why?
|
Neoplasm Transplantation | 1 | 1994 | 1519 | 0.010 |
Why?
|
Neuropsychological Tests | 1 | 1995 | 1178 | 0.010 |
Why?
|
Gene Amplification | 1 | 1993 | 731 | 0.010 |
Why?
|
Pneumonia, Viral | 1 | 1999 | 715 | 0.010 |
Why?
|
Lymphocyte Activation | 1 | 1995 | 1688 | 0.010 |
Why?
|
Probability | 1 | 1992 | 866 | 0.010 |
Why?
|
Hydrocortisone | 1 | 1992 | 388 | 0.010 |
Why?
|
Skin | 2 | 1986 | 1259 | 0.010 |
Why?
|
Chromosome Disorders | 1 | 1992 | 417 | 0.010 |
Why?
|
Immunologic Factors | 1 | 1994 | 649 | 0.010 |
Why?
|
Amino Acid Sequence | 1 | 1996 | 4233 | 0.010 |
Why?
|
Mice, SCID | 1 | 1994 | 1869 | 0.010 |
Why?
|
Radiography | 1 | 1994 | 1904 | 0.010 |
Why?
|
Survivors | 1 | 1995 | 1031 | 0.010 |
Why?
|
Leucovorin | 1 | 1990 | 332 | 0.010 |
Why?
|
Cognition | 1 | 1995 | 968 | 0.010 |
Why?
|
Tumor Suppressor Proteins | 1 | 1996 | 1823 | 0.010 |
Why?
|
Transcription, Genetic | 1 | 1996 | 3154 | 0.000 |
Why?
|
Diagnosis, Differential | 1 | 1997 | 4744 | 0.000 |
Why?
|
Metabolic Clearance Rate | 1 | 1987 | 231 | 0.000 |
Why?
|
Brachytherapy | 1 | 1993 | 977 | 0.000 |
Why?
|
Research Design | 1 | 1994 | 1544 | 0.000 |
Why?
|
Random Allocation | 1 | 1987 | 703 | 0.000 |
Why?
|
Rh-Hr Blood-Group System | 1 | 1986 | 24 | 0.000 |
Why?
|
Rosette Formation | 1 | 1985 | 38 | 0.000 |
Why?
|
Radiotherapy | 1 | 1993 | 1824 | 0.000 |
Why?
|
Infusions, Parenteral | 1 | 1986 | 191 | 0.000 |
Why?
|
Mitoxantrone | 1 | 1986 | 216 | 0.000 |
Why?
|
Peritoneum | 1 | 1986 | 150 | 0.000 |
Why?
|
Antigens, Surface | 1 | 1986 | 295 | 0.000 |
Why?
|
Azacitidine | 1 | 1992 | 1149 | 0.000 |
Why?
|
ABO Blood-Group System | 1 | 1986 | 127 | 0.000 |
Why?
|
Antibody Formation | 1 | 1986 | 383 | 0.000 |
Why?
|
DNA, Neoplasm | 1 | 1990 | 1910 | 0.000 |
Why?
|
Spleen | 1 | 1986 | 676 | 0.000 |
Why?
|
Immunoenzyme Techniques | 1 | 1986 | 1165 | 0.000 |
Why?
|
Patient Isolation | 1 | 1983 | 25 | 0.000 |
Why?
|
Antibodies | 1 | 1985 | 838 | 0.000 |
Why?
|
Preoperative Care | 1 | 1988 | 1529 | 0.000 |
Why?
|
Neoplasm Staging | 1 | 1996 | 13658 | 0.000 |
Why?
|
Radiotherapy Dosage | 1 | 1988 | 3842 | 0.000 |
Why?
|
Antigen-Antibody Reactions | 1 | 1980 | 92 | 0.000 |
Why?
|
Radioimmunoassay | 1 | 1980 | 191 | 0.000 |
Why?
|
Cardiomyopathies | 1 | 1986 | 610 | 0.000 |
Why?
|
Demyelinating Diseases | 1 | 1980 | 77 | 0.000 |
Why?
|
Megakaryocytes | 1 | 1980 | 104 | 0.000 |
Why?
|